We are live on ! Find out more
Macquarie Group

Macquarie Group Portfolio holdings

AUM $16.8B
1-Year Est. Return 27.39%
This Fund
S&P 500
This Quarter Est. Return
+5.05%
1 Year Est. Return
+27.39%
3 Year Est. Return
+81.07%
5 Year Est. Return
+109.03%
10 Year Est. Return
+396.55%
AUM
$56.6B
AUM Growth
+$810M
Cap. Flow
-$1.48B
Cap. Flow %
-2.61%
Top 10 Hldgs %
13.48%
Holding
2,531
New
387
Increased
823
Reduced
1,010
Closed
163

Top Buys

Rank Stock Value
1
CME icon
CME Group
CME
+$94.6M
2
AMAT icon
Applied Materials
AMAT
+$91.8M
3
ANET icon
Arista Networks
ANET
+$73.5M
4
ILMN icon
Illumina
ILMN
+$50.4M
5
TV icon
Televisa
TV
+$49.9M

Top Sells

Rank Stock Value
1
MRO
Marathon Oil Corporation
MRO
+$149M
2
DLTR icon
Dollar Tree
DLTR
+$140M
3
INTC icon
Intel
INTC
+$129M
4
NVDA icon
NVIDIA
NVDA
+$104M
5
NLSN
Nielsen Holdings plc
NLSN
+$84.8M

Sector Composition

Rank Sector Weight
1 Healthcare 15.88%
2 Financials 15.63%
3 Technology 12.66%
4 Energy 10.4%
5 Industrials 9.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMUX icon
2251
Immunic
IMUX
$182M
$9K ﹤0.01%
+4
New +$8.84K
KPTI icon
2252
Karyopharm Therapeutics
KPTI
$168M
$9K ﹤0.01%
+60
New +$9.64K
KURA icon
2253
Kura Oncology
KURA
$922M
$9K ﹤0.01%
+600
New +$8.84K
MCRB icon
2254
Seres Therapeutics
MCRB
$48M
$9K ﹤0.01%
+45
New +$9.24K
PRQR icon
2255
ProQR Therapeutics
PRQR
$243M
$9K ﹤0.01%
+2,900
New +$10.4K
RYTM icon
2256
Rhythm Pharmaceuticals
RYTM
$7B
$9K ﹤0.01%
+300
New +$7.93K
SYRE icon
2257
Spyre Therapeutics
SYRE
$8.87B
$9K ﹤0.01%
+70
New +$8.56K
VKTX icon
2258
Viking Therapeutics
VKTX
$4.04B
$9K ﹤0.01%
+2,100
New +$6.1K
XENE icon
2259
Xenon Pharmaceuticals
XENE
$6.32B
$9K ﹤0.01%
+3,300
New +$8.97K
MTVA
2260
MetaVia Inc
MTVA
$7.64M
– –
0
– –
SYRS
2261
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$9K ﹤0.01%
+90
New +$12.1K
KA
2262
DELISTED
Kineta, Inc. Common Stock
KA
$9K ﹤0.01%
+11
New +$4.22K
VBIV
2263
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$9K ﹤0.01%
+70
New +$8.61K
TCON
2264
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$9K ﹤0.01%
+14
New +$8.45K
TGH
2265
DELISTED
Textainer Group Holdings limited
TGH
$9K ﹤0.01%
+400
New +$8.26K
CCXI
2266
DELISTED
ChemoCentryx, Inc.
CCXI
$9K ﹤0.01%
1,500
-7,131
-83% -$48.9K
ATHX
2267
DELISTED
Athersys, Inc. Common Stock
ATHX
$9K ﹤0.01%
+188
New +$9.1K
KDMN
2268
DELISTED
Kadmon Holdings, Inc.
KDMN
$9K ﹤0.01%
+2,400
New +$8.57K
STML
2269
DELISTED
Stemline Therapeutics, Inc.
STML
$9K ﹤0.01%
+600
New +$8.02K
ANTH
2270
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$9K ﹤0.01%
+5,500
New +$9.46K
IMDZ
2271
DELISTED
Immune Design Corp.
IMDZ
$9K ﹤0.01%
+2,300
New +$12.5K
AST
2272
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
$9K ﹤0.01%
+3,800
New +$9.62K
ADVM
2273
DELISTED
Adverum Biotechnologies
ADVM
$8K ﹤0.01%
+240
New +$7.9K
AFMD
2274
DELISTED
Affimed
AFMD
$8K ﹤0.01%
+650
New +$12.3K
ATNM icon
2275
Actinium Pharmaceuticals
ATNM
$27M
$8K ﹤0.01%
+423
New +$8.51K
89 90
91
92 93

Similar funds

AIMCA
Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $16.7B AUM 23.27% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return

Macquarie Group's Q4 2017 Portfolio in Review

As of Q4 2017, Macquarie Group held 2,531 positions worth $56.6B, up 1.5% from $55.7B the previous quarter. Its ten largest holdings account for 13% of the portfolio.

Macquarie Group's Q4 2017 filing shows 387 new, 823 increased, 1,010 reduced and 163 closed positions. Its largest new stake was WPP: 343,817 shares worth $31.1M. The largest sale was Marathon Oil Corporation, an estimated $149M.

By sector, the portfolio is most concentrated in Healthcare at 16% of assets, down from 16% a quarter earlier, followed by Financials and Technology.

  • Macquarie Group's largest Q4 2017 buy was WPP: 343,817 shares worth $31.1M.
  • Macquarie Group added most to CME Group in Q4 2017, an estimated $94.6M increase.
  • Macquarie Group's biggest Q4 2017 reduction was Marathon Oil Corporation, cutting an estimated $149M.
  • Macquarie Group fully exited Alexander & Baldwin in Q4 2017, selling an estimated $30.1M.
  • Macquarie Group's ten largest holdings make up 13% of its $56.6B portfolio in Q4 2017.
  • Macquarie Group opened 387 new positions and closed 163 in Q4 2017.
  • Macquarie Group's portfolio value rose 1.5% quarter-over-quarter to $56.6B.

Based on Macquarie Group's 13F filing for Q4 2017, filed 15 Feb 2018.